Caladrius Biosciences
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
You can watch CLBS and buy or sell other stocks, ETFs, and their options commission-free!About CLBS
Lisata Therapeutics, Inc. is a clinical-stage pharmaceutical company, which engages in the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other major diseases. Its product, Certepetide, is designed to activate a novel uptake pathway that allows co-administered or tethered anti-cancer drugs to target and penetrate tumors.
CEODavid J. Mazzo, PhD
CEODavid J. Mazzo, PhD
Employees26
Employees26
HeadquartersBasking Ridge, New Jersey
HeadquartersBasking Ridge, New Jersey
Founded1980
Founded1980
Employees26
Employees26
CLBS Key Statistics
Market cap23.29M
Market cap23.29M
Price-Earnings ratio-0.99
Price-Earnings ratio-0.99
Dividend yield—
Dividend yield—
Average volume49.18K
Average volume49.18K
High today—
High today—
Low today—
Low today—
Open price—
Open price—
Volume0.00
Volume0.00
52 Week high$4.11
52 Week high$4.11
52 Week low$1.81
52 Week low$1.81
Stock Snapshot
Caladrius Biosciences(CLBS) stock is priced at $2.66, giving the company a market capitalization of 23.29M. It carries a P/E multiple of -0.99.
On 2026-01-08, Caladrius Biosciences(CLBS) shares started trading at —, with intraday highs of — and lows of —.
Trading volume for Caladrius Biosciences(CLBS) stock has reached 0, versus its average volume of 49.18K.
The stock's 52-week range extends from a low of $1.81 to a high of $4.11.
The stock's 52-week range extends from a low of $1.81 to a high of $4.11.
People also own
Based on the portfolios of people who own CLBS. This list is generated using Robinhood data, and it’s not a recommendation.